Literature DB >> 26392492

Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target.

A Lepak1, K Marchillo1, J VanHecker1, D Andes2.   

Abstract

Dalbavancin is a novel lipoglycopeptide with activity against Staphylococcus aureus, including glycopeptide-resistant isolates. The in vivo investigation reported here tested the effects of this antibiotic against seven S. aureus isolates with higher MICs, including several vancomycin-intermediate strains. Results of 1-log kill and 2-log kill were achieved against seven and six of the isolates, respectively. The mean free-drug area under the concentration-time curve (fAUC)/MIC values for net stasis, 1-log kill, and 2-log kill were 27.1, 53.3, and 111.1, respectively.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26392492      PMCID： PMC4649188          DOI： 10.1128/AAC.01717-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  Vancomycin resistance in Staphylococcus aureus.

Authors:  C C John
Journal:  N Engl J Med       Date:  1999-07-15       Impact factor: 91.245

2.  The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.

Authors:  K Sieradzki; R B Roberts; S W Haber; A Tomasz
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

3.  Community-associated MRSA--resistance and virulence converge.

Authors:  Henry F Chambers
Journal:  N Engl J Med       Date:  2005-04-07       Impact factor: 91.245

4.  Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.

Authors:  Issam Raad; Rabih Darouiche; Jose Vazquez; Arnold Lentnek; Ray Hachem; Hend Hanna; Beth Goldstein; Tim Henkel; Elyse Seltzer
Journal:  Clin Infect Dis       Date:  2005-01-07       Impact factor: 9.079

Review 5.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

6.  Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.

Authors:  T L Smith; M L Pearson; K R Wilcox; C Cruz; M V Lancaster; B Robinson-Dunn; F C Tenover; M J Zervos; J D Band; E White; W R Jarvis
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

7.  The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.

Authors:  Hasan Cenk Mirza; Banu Sancak; Deniz Gür
Journal:  Microb Drug Resist       Date:  2015-04-28       Impact factor: 3.431

Review 8.  Origin, structure, and activity in vitro and in vivo of dalbavancin.

Authors:  Adriano Malabarba; Beth P Goldstein
Journal:  J Antimicrob Chemother       Date:  2005-03       Impact factor: 5.790

Review 9.  Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.

Authors:  Mary Beth Dorr; Daniela Jabes; Marco Cavaleri; James Dowell; Giorgio Mosconi; Adriano Malabarba; Richard J White; Timothy J Henkel
Journal:  J Antimicrob Chemother       Date:  2005-03       Impact factor: 5.790

10.  Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.

Authors:  Elyse Seltzer; Mary Beth Dorr; Beth P Goldstein; Marc Perry; James A Dowell; Tim Henkel
Journal:  Clin Infect Dis       Date:  2003-10-17       Impact factor: 9.079
View more
  9 in total

1.  Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections.

Authors:  Pier Giorgio Cojutti; Matteo Rinaldi; Eleonora Zamparini; Nicolò Rossi; Sara Tedeschi; Matteo Conti; Federico Pea; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2021-03-01       Impact factor: 5.191

2.  Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients.

Authors:  E T Van Matre; I Teitelbaum; T H Kiser
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

3.  Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.

Authors:  Alexander J Lepak; Miao Zhao; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.

Authors:  Kyle C Molina; Matthew A Miller; Scott W Mueller; Edward T Van Matre; Martin Krsak; Tyree H Kiser
Journal:  Clin Pharmacokinet       Date:  2021-12-21       Impact factor: 5.577

5.  Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Dalbavancin.

Authors:  Ute Chiriac; Heike Rau; Otto R Frey; Anka C Röhr; Sabrina Klein; Anna L Meyer; Benedict Morath
Journal:  Antibiotics (Basel)       Date:  2022-04-19

6.  Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: Results of a network meta-analysis.

Authors:  Julian F Guest; Jaime Esteban; Anton G Manganelli; Andrea Novelli; Giuliano Rizzardini; Miquel Serra
Journal:  PLoS One       Date:  2017-11-14       Impact factor: 3.240

7.  Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis.

Authors:  Timothy J Carrothers; Jason T Chittenden; Ian Critchley
Journal:  Clin Pharmacol Drug Dev       Date:  2019-05-14

8.  Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring.

Authors:  Pier Giorgio Cojutti; Sara Tedeschi; Milo Gatti; Eleonora Zamparini; Marianna Meschiari; Paola Della Siega; Maria Mazzitelli; Laura Soavi; Raffaella Binazzi; Elke Maria Erne; Marco Rizzi; Anna Maria Cattelan; Carlo Tascini; Cristina Mussini; Pierluigi Viale; Federico Pea
Journal:  Antibiotics (Basel)       Date:  2022-07-24

9.  Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion.

Authors:  Urania Rappo; Michael W Dunne; Sailaja Puttagunta; James S Baldassarre; Shengfang Su; Daksha Desai-Krieger; Megumi Inoue
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.